Safety and Efficacy of Novel Combination Therapy with Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide in Newly Diagnosed Multiple Myeloma: Initial Results from the Phase I/II MultiCenter EVOLUTION Study
Publication
, Conference
Kumar, S; Flinn, IW; Noga, SJ; Hari, P; Rifkin, RM; Callander, NS; Bhandari, M; Wolf, JL; Gasparetto, C; Krishnan, A; Grosman, DD; Glass, J ...
Published in: BLOOD
November 16, 2008
Duke Scholars
Published In
BLOOD
ISSN
0006-4971
Publication Date
November 16, 2008
Volume
112
Issue
11
Start / End Page
41 / 42
Location
San Francisco, CA
Publisher
AMER SOC HEMATOLOGY
Conference Name
50th Annual Meeting of the American-Society-of-Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Kumar, S., Flinn, I. W., Noga, S. J., Hari, P., Rifkin, R. M., Callander, N. S., … Rajkumar, S. V. (2008). Safety and Efficacy of Novel Combination Therapy with Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide in Newly Diagnosed Multiple Myeloma: Initial Results from the Phase I/II MultiCenter EVOLUTION Study. In BLOOD (Vol. 112, pp. 41–42). San Francisco, CA: AMER SOC HEMATOLOGY.
Kumar, Shaji, Ian W. Flinn, Stephen J. Noga, Parameswaran Hari, Robert M. Rifkin, Natalie Scott Callander, Manish Bhandari, et al. “Safety and Efficacy of Novel Combination Therapy with Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide in Newly Diagnosed Multiple Myeloma: Initial Results from the Phase I/II MultiCenter EVOLUTION Study.” In BLOOD, 112:41–42. AMER SOC HEMATOLOGY, 2008.
Kumar S, Flinn IW, Noga SJ, Hari P, Rifkin RM, Callander NS, et al. Safety and Efficacy of Novel Combination Therapy with Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide in Newly Diagnosed Multiple Myeloma: Initial Results from the Phase I/II MultiCenter EVOLUTION Study. In: BLOOD. AMER SOC HEMATOLOGY; 2008. p. 41–2.
Kumar, Shaji, et al. “Safety and Efficacy of Novel Combination Therapy with Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide in Newly Diagnosed Multiple Myeloma: Initial Results from the Phase I/II MultiCenter EVOLUTION Study.” BLOOD, vol. 112, no. 11, AMER SOC HEMATOLOGY, 2008, pp. 41–42.
Kumar S, Flinn IW, Noga SJ, Hari P, Rifkin RM, Callander NS, Bhandari M, Wolf JL, Gasparetto C, Krishnan A, Grosman DD, Glass J, Sahovic EA, Shi H, Webb IJ, Richardson P, Rajkumar SV. Safety and Efficacy of Novel Combination Therapy with Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide in Newly Diagnosed Multiple Myeloma: Initial Results from the Phase I/II MultiCenter EVOLUTION Study. BLOOD. AMER SOC HEMATOLOGY; 2008. p. 41–42.
Published In
BLOOD
ISSN
0006-4971
Publication Date
November 16, 2008
Volume
112
Issue
11
Start / End Page
41 / 42
Location
San Francisco, CA
Publisher
AMER SOC HEMATOLOGY
Conference Name
50th Annual Meeting of the American-Society-of-Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology